Comparison of gonadotropin-releasing hormone agonists and orchiectomy: Effects of androgen-deprivation therapy

JAMA Oncology

Volumn 2, Issue 4, 2016, Pages 500-507

  Sun, Maxine ^a   Choueiri, Toni K ^b   Hamnvik, Ole Petter R ^a,c   Preston, Mark A ^a   De Velasco, Guillermo ^b   Jiang, Wei ^a   Loeb, Stacy ^d   Nguyen, Paul L ^a   Trinh, Quoc Dien ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADVERSE EFFECTS; AGED; AGONISTS; CANCER REGISTRY; COMPARATIVE STUDY; HUMAN; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM;

EID: 84986253537     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4917     Document Type: Article

References (31)

1. Byar D, Corle D. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI monographs. Pub Natl Cancer Inst. 1988;7:165-170.
2. ShelleyMD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9-17.
3. HussainM, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013; 368(14):1314-1325.
4. Higano CS. Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw. 2014;12(5):727-733.
5. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013;31 (16):2029-2036.
6. Botrel TE, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14(9):9.
7. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-1524.
8. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
9. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979-3983.
10. Gandaglia G, Sun M, Hu JC, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. 2014;66(6):1125-1132.
11. Smith MR, LeeWC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897-7903.
12. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
13. Krahn M, Bremner KE, Tomlinson G, et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int. 2011;108(10):1588-1596.
14. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3): 565-573.
15. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
16. Wu LM, Diefenbach MA, GordonWA, Cantor JB, Cherrier MM. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study. Urol Oncol. 2013;31(8):1533-1538.
17. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61(6):1119-1128.
18. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12):1258-1267.
19. Gandaglia G, Sammon JD, Chang SL, et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014;32(14):1419-1426.
20. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46(3):399-424.
21. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
22. Szychowski JM, Roth DL, Clay OJ, Mittelman MS. Patient death as a censoring event or competing risk event in models of nursing home placement. Stat Med. 2010;29(3):371-381.
23. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6): 1021-1024.
24. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.
25. Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol. 1998;138(1):51-58.
26. Zarotsky V, HuangMY, CarmanW, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2(6):819-834.
27. Eldar-Geva T, Liberty G, Chertin B, et al. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. Eur J Endocrinol. 2010;162(1):177-181.
28. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology. 1989;33(5)(suppl):57-62.
29. Bonzani R, Stricker J, Peabody J. Quality of life comparison of lupron and orchiectomy. J Urol. 1996;155(suppl):611A.
30. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19(17): 3750-3757.
31. Engels EA, Pfeiffer RM, RickerW, WheelerW, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174(7):860-870.